- The U.S. District Court for the District of Delaware has granted Clarus Therapeutics' motion for summary judgment against remaining patents in a patent infringement case brought by Lipocine Inc LPCN regarding Clarus's oral testosterone replacement product, Jatenzo.
- Federal Circuit Judge found all of the asserted Lipocine patents claims invalid.
- Clarus's defense of inequitable conduct remains pending, and its disposition is expected to be addressed by Clarus and the Court at a future date.
- Lipocine brought the action for patent infringement against Clarus in April 2019, arising out of Clarus's marketing of Jatenzo, an oral testosterone replacement product approved by the FDA in March 2019 and launched in March 2020.
- Price Action: LPCN shares are down 13.7% at $1.18 during the market session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
